Table 2.
CHARACTERISTICS OF PATIENTS WITH HBVr
| Age | Sex | Disease | Time of HBVr (Months) | Outcome | Time of HBVr to Last Follow‐Up | Antiviral Treatment | HBV DNA Suppression (Months) | HBsAg Loss After HBVr (Months) | ALT (IU/mL) at HBVr | INR at HBVr | MELD Score at HBVr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 28 | M | T‐NHL | 13 | survival | 18 | Lamivudin | 9 | ‐ | 31 | 0.99 | 7 |
| 2 | 36 | M | AML | 13 | death (sepsis) | 14 | Entecavir | ‐ | ‐ | 157 | 1.06 | 6 |
| 3 | 54 | M | AML | 2 | survival | 7 | Entecavir | NA (lost to follow‐up) | ‐ | 20 | 0.91 | 6 |
| 4 | 54 | F | AML | 44 | survival | 83 | Lamivudin | 5 | 5 | 88 | 0.90 | 6 |
| 5 | 41 | M | MDS | 30 | survival | 65 | Lamivudin, Tenofovir | 40 | 45 | 384 | 0.83 | 7 |
| 6 | 61 | F | AML | 39 | survival | 54 | Entecavir | ‐ | ‐ | 26 | 0.95 | 6 |
| 7 | 61 | F | AML | 67 | survival | 6 | Tenofovir | 6 | ‐ | 159 | NA | |
| 8 | 57 | F | sNHL | 37 | survival | 27 | Entecavir | ‐ | ‐ | 34 | 0.87 | 8 |
| 9 | 48 | M | AML | 25 | death | 22 | Entecavir | 4 | 11 | 617 | 1.66 | 27 |
| 10 | 55 | M | CML | 28 | survival | 11 | ‐ | 4 | 4 | 53 | 1.01 | 11 |
| 11 | 40 | M | HL | 26 | death (recurrence) | 0 | ‐ | NA (death after 1 week) | ‐ | 68 | 1.18 | 18 |
| 12 | 57 | M | IMF | 11 | death (liver failure) | 1 | Lamivudin | NA (death after 5 weeks) | ‐ | 229 | 1.44 | 19 |
| 13 | 61 | F | AML | 25 | survival | 16 | Adefovir | 1 | 2 | 1125 | 1.27 | 18 |
Abbreviations: ALT, alanine transaminase; AML, acute myeloid leukemia; CML, chronic myeloid leukemia; HL, Hodgkin lymphoma; IMF, idiopathic osteomyelofibrosis; INR, international normalized ratio; MDS, myelodysplastic syndrome; MELD, model for end‐stage liver disease; NA, unknown; sNHL, secondary non‐Hodgkin lymphoma; T‐NHL, T‐cell non‐Hodgkin lymphoma.